Significant advancements in oncology include: UNC Lineberger’s symposium highlighting progress in cancer research; novel dual-target therapies aiming at colorectal and breast cancers; innovative biomarker discovery through spatial and single-cell omics; and CAR macrophage therapy for lung metastasis. Moreover, Tyligand Bioscience introduced new KRAS mutant inhibitors for cancer treatment. These developments underscore a growing nexus between immunotherapy, precision medicine, and molecular targeting to improve clinical outcomes.